Company: HURA
Filing Date: 2025-05-06
Form Type: S-4/A
Source: 0001193125-25-113920
Chunk: 664

Company: TuHURA Biosciences, Inc./NV
Filing Date: 2025-05-06
Form: S-4/A
Chunk 664
---
 the Merger Agreement is terminated, within ten days following the date of such termination.No proceeds of the CTF Note may be used for any other purposes, including without limitation, paying any operating, transaction or other expenses of Kineta. The CTF Note includes customary protective provisions for the benefit of TuHURA as a lender.Under the terms of the CTF Agreement, previous advances made by TuHURA to Kineta prior to the execution of the CTF Agreement with the intent of helping Kineta to contract research organization and other vendors reasonably acceptable to TuHURA for the continued development of the KVA12123 assets and related clinical trials (collectively, the “Existing Advances”), will aggregate with the principal of the additional funds advanced subsequent to December 11, 2024 (see below and as reflected within Pro Forma AdjustmentAin Note 4 of the notes to the unaudited pro forma condensed combined financial information), however they will not accrue any interest.The total amount of funding able to be advanced under the terms of the CTF Agreement, notwithstanding the mutual consent of both TuHURA and Kineta, is an aggregate principal amount equal to the Existing Advances plus $900,000. There were four Existing Advances made between September 18, 2024, and December 9, 2024 that totaled $694,503, which will be included in the aggregate principal amount for the purposes of making any future advances under the total CTF Agreement’s funding cap (i.e. $900,000plus$694,503, or $1,594,503, as of the date of the CTF Agreement’s execution). The Existing Advances funded prior to the execution of both the CTF Agreement as well as the Merger Agreement represent advances already made by TuHURA to Kineta in connection with the exclusivity agreement and are included as a credit against the cash component of the Merger Consideration to be paid to Kineta stockholders in the Mergers. Any future Advances made under the CTF Agreement will not count towards the Merger Consideration. As of December 31, 2024, only the four Existing Advances described in the CTF Agreement had been made for $694,503. Through the date of this unaudited pro forma condensed combined financial information, the total subsequent CTF Notes that have been made aggregate to an additional principal amount of $851,809 funded under the CTF agreement (reflected within Pro Forma AdjustmentAin Note 4 of the notes to the una